The American Heart Association is backing an AI startup aimed at improving detection of hard-to-diagnose conditions like cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The company, named Ultromics, offers a platform that analyzes routine echocardiograms to help clinicians catch disease earlier, particularly for women who are more likely to be missed. The…
Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to…
BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.
GE HealthCare made a slew of announcements at RSNA 2024, including an acquisition, new machines for mammography and SPECT/CT imaging, and new AI features to help improve radiologist workflows. The post 4 Announcements GE HealthCare Made at RSNA 2024 appeared first on MedCity News.
This policy watch discusses key provisions in the draft 2025 budget reconciliation legislation that are aimed at limiting health coverage for immigrant families.
Pharmacogenomics offers an opportunity to help shield female cardiology patients from some of the negative impacts by helping to streamline the process from diagnosis to finding a successful treatment for that patient. The post Pharmacogenomics Can Help Buffer Female Cardiac Patients From Impacts Of Funding Cuts appeared first on MedCity News.
The federal Consumer Financial Protection Bureau on Tuesday issued new regulations barring medical debts from American credit reports, enacting a major new consumer protection just days before President Joe Biden is set to leave office. The rules ban credit agencies from including medical debts on consumers’ credit reports and prohibit lenders from considering medical information…
[Sponsored] At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch. The post The Human Algorithm: What AI Can’t Replace in Pharma Engagement appeared first on MedCity News.
Worried that President-elect Donald Trump will curtail federal efforts to take on the nation’s medical debt problem, patient and consumer advocates are looking to states to help people who can’t afford their medical bills or pay down their debts. “The election simply shifts our focus,” said Eva Stahl, who oversees public policy at Undue Medical…
Nonprofit population health services company starts with internal customers but plans to expand